The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
Open accessAbstract
BACKGROUND: Body composition is an important predictor of drug toxicity and outcome. Ipilimumab (Ipi), a monoclonal antibody used to treat metastatic melanoma, has specific toxicities. No validated biomarkers that predict Ipi toxicity and efficacy exist. Also, the impact of Ipi on body composition has not been established. METHODS: Patients with metastatic melanoma treated with Ipi between 2009 and 2015 were included. Body composition was assessed by computed tomography at baseline and after four cycles of Ipi. Sarcopenia and low muscle attenuation (MA) were defined using published cut-points. All adverse events (AEs) and immune-related AEs (irAEs) were recorded (Common Terminology Criteria For Adverse Event V.4.0). RESULTS: Eighty-four patients were included in this study (62% male, median age 54 years). At baseline, 24% were sarcopenic and 33% had low MA. On multivariate analysis, sarcopenia and low MA were significantly associated with high-grade AEs (OR=5.34, 95% CI: 1.15-24.88, P=0.033; OR=5.23, 95% CI: 1.41-19.30, P=0.013, respectively), and low MA was associated with high-grade irAEs (OR=3.57, 95% CI: 1.09-11.77, P=0.036). Longitudinal analysis (n=59) revealed significant reductions in skeletal muscle area (SMA), total body fat-free mass, fat mass (all P<0.001) and MA (P=0.030). Mean reduction in SMA was 3.3%/100 days (95% CI: -4.48 to -1.79%, P<0.001). A loss of SMA ⩾7.5%/100 days (highest quartile) was a significant predictor of overall survival in multivariable Cox regression analysis (HR: 2.1, 95% CI: 1.02-4.56, P=0.046). CONCLUSIONS: Patients with sarcopenia and low MA are more likely to experience severe treatment-related toxicity to Ipi. Loss of muscle during treatment was predictive of worse survival. Treatments to increase muscle mass and influence outcome warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692
Mitsiopoulos, N., Baumgartner, R. N., Heymsfield, S. B., Lyons, W., Gallagher, D., & Ross, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.115 · Cited by 1,522
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“Such adverse effect can be treated effectively with immunosuppressive agents (Weber et al , 2012).”
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Human Body Composition: Advances in Models and Methods
B. Heymsfield, S., Wang, Z., Baumgartner, R. N., & Ross, R. (1997) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.17.1.527 · Cited by 527
Pichard, C., Kyle, U. G., Morabia, A., Perrier, A., Vermeulen, B., & Unger, P. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.613 · Cited by 392 · cited 1×
“…and its relationship to adverse clinical outcomes has been extensively studied and shown to be associated with increase length of hospital stay (Pichard et al , 2004), postoperative infections (Lieffers et al , 2012), functional impairment and decreased survival in both malignant (Tan et al ,…”
Cited by
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Myosteatosis and prognosis in cancer: Systematic review and meta-analysis
Aleixo, G. F. P., Shachar, S. S., Nyrop, K. A., Muss, H. B., Malpica, L., & Williams, G. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102839 · Cited by 345
Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.779691 · Cited by 344
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Implications of low muscle mass across the continuum of care: a narrative review
Prado, C. M., Purcell, S. A., Alish, C., Pereira, S. L., Deutz, N. E., Heyland, D. K., Goodpaster, B. H., Tappenden, K. A., & Heymsfield, S. B. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1511918 · Cited by 286
Elliott, J. A., Doyle, S. L., Murphy, C. F., King, S., Guinan, E. M., Beddy, P., Ravi, N., & Reynolds, J. V. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002398 · Cited by 281
Cachexia: A systemic consequence of progressive, unresolved disease
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, B. J., Cespedes Feliciano, E. M., Coll, A. P., Dunne, R. F., Goncalves, M. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.028 · Cited by 260
Metadata
- Authors
- Daly, L. E., Power, D. G., O'Reilly, Á., Donnellan, P., Cushen, S. J., O'Sullivan, K., Twomey, M., Woodlock, D. P., Redmond, H. P., & Ryan, A. M.
- Venue
- British Journal of Cancer
- Published
- 2017-01
- Volume
- 116
- Issue
- 3
- Pages
- 310-317
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2570443512
- Cited by
- 187
- References
- 8
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.